Direct Thrombin Inhibitor
40 drugs across 10 manufacturers|34 Generic,6 Brand
The Direct Thrombin Inhibitor class contains 40 NDCs from 10 manufacturers (34 generic, 6 brand), at an average NADAC of $1.17 per unit. Every drug, manufacturer, and price in this FDA-defined pharmacologic class is listed below.
Total Drugs
40
34G / 6B
Manufacturers
10
Avg $1.1725/unit
Avg 7d Change
-3.01%
Across 38 drugs with changes
7d Activity
of 40 total drugs
Class Price Trend
Monthly average NADAC price per unit, split by generic and brand
Manufacturer Breakdown
10 manufacturers producing drugs in this therapeutic class(3 pricing outliers)
Follow this class across the site
These links connect the therapeutic class page to the specific suppliers, markets, and trend surfaces that help users keep exploring.
Top supplier
Boehringer Ingelheim Pharmaceuticals Inc. manufacturer profile
Review the supplier with the strongest product footprint inside this therapeutic class.
Lead market
Dabigatran Etexilate market page
Move from the therapeutic class into the molecule that appears most often in this class-specific portfolio.
Trend hub
Latest trend hub
Compare this class against the rest of the weekly NADAC trend surface.
Guide
Understanding NADAC pricing
Use the explainer when you need a plain-English refresher on how these class-level numbers are published and interpreted.
Frequently Asked Questions
How many drugs are in the Direct Thrombin Inhibitor class?
The Direct Thrombin Inhibitor class contains 40 NDCs from 10 manufacturers — 34 generic and 6 brand products.
What is the average price of Direct Thrombin Inhibitor drugs?
The average NADAC for the Direct Thrombin Inhibitor class is $1.1725 per unit across 40 NDCs.
Is generic cheaper than brand in the Direct Thrombin Inhibitor class?
Among products priced per EA, the average generic NADAC in this class is $0.8210, versus $3.1644 for brand — brand products average about 3.9× the generic price.
Which manufacturers make Direct Thrombin Inhibitor drugs?
10 manufacturers make drugs in the Direct Thrombin Inhibitor class. Ranked by number of NDCs, the largest are Boehringer Ingelheim Pharmaceuticals Inc. (6), Camber Pharmaceuticals Inc. (6), Alembic Pharmaceuticals Inc. (6), Major Pharmaceuticals (5), Dr. Reddy's Laboratories Inc. (3).
How has Direct Thrombin Inhibitor pricing changed recently?
Over the past 7 days, 2 NDCs in this class rose and 36 fell, with a class-wide average change of -3.0%.